BioCentury reported a surge of KRAS G12D-targeting programs, with more than 20 initiatives launched in the past year as companies move to drug the most common KRAS mutation in solid tumors. The coverage cataloged small molecules, biologics and combination strategies entering preclinical and clinical stages, and noted the competitive landscape is accelerating quickly. KRAS G12D is a recurrent oncogenic driver in pancreatic and colorectal cancers; targeting it directly has been a longstanding challenge. The recent wave of programs reflects improved drug-design strategies and growing investor appetite for precision oncology assets that can address historically 'undruggable' mutations.